Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

• Autors principals: Kim Rand (Autor), Juan Manuel Ramos-Goñi (Autor), Bülent Akmaz (Autor), Laia Solé-Feu (Autor), José-Carlos A (Autor)
• Format: Llibre
• Publicat: Adis, Springer Healthcare, 2023-10-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Abstract Introduction Lebrikizumab and dupilumab are monoclonal antibodies approved for treating moderate-to-severe atopic dermatitis (AD). Both have demonstrated efficacy and safety over the 16-week SOLOs and ADvocate trials. However, AD is a chronic and relapsing inflammatory disease, and the long...